GlassScriptPhysician profile
John Lee Mcneill
NPI 1205812898
$1,409.19
in general payments reported to CMS, 2019-2025
21 companies · $55.74 in 2025
The $55.74 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $66.59 · 2021: $241 · 2022: $453 · 2023: $181 · 2024: $46.25 · 2025: $55.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $283.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $306.85 | 2019-2023 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $204.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $123.04 | 2019-2022 | |
| Antares Pharma, INC. | $116.68 | 2022-2023 | Tlando, Nocdurna, Xyosted |
| Astrazeneca Pharmaceuticals LP | $77.48 | 2022-2025 | Farxiga |
| Amarin Pharma, INC. | $73.09 | 2019-2022 | |
| Btg International INC. | $72.68 | 2019 | |
| Siemens Medical Solutions USA, INC. | $62.45 | 2022 | |
| Purdue Pharma L.P. | $54.30 | 2022-2023 | Nalmefene Hydrochloride |
| Novartis Pharmaceuticals Corporation | $54.09 | 2022 | |
| Amgen INC. | $53.04 | 2023-2024 | Otezla, Repatha |
| Pfizer INC. | $40.79 | 2019-2023 | |
| Glaxosmithkline, LLC. | $33.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.13 | 2022 | |
| Exact Sciences Corporation | $21.98 | 2025 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.11 | 2023 | Belsomra, Steglatro |
| Esperion Therapeutics, INC. | $17.13 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.76 | 2022 | |
| Lilly USA, LLC | $13.73 | 2023 | Mounjaro |
| Horizon Therapeutics Plc | $12.63 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.